Trunome has raised INR 1.5 crores from shark tank season 2. Pitcher asked for 1.5 crores rupees for 1% equity in the company at the valuation of 150 crores. All four sharks, Piyush, Anupam, Veenita and Aman, invested in this startup.
First, Piyush offered 1.5 crores at 2% equity. Then Anupam gave an offer of 1.5 crores at 1.75% equity. Veenita offered 75 lakhs for 1% equity and 75 lakhs interest-free debt. Then all four sharks, Piyush, Anupam, Veenita and Aman, gave a combined offer of 1.5 crores for 2% equity. And pitcher gave a counteroffer of 3 crores for 2.5% equity.
Also Read GROWiT has raised INR 50 lakhs from shark tank season 2. Namita and Piyush have invested in this startup. The owner made an ask of 1 crore rupees for 1% equity in the company.
About The Trunome
The founders of the company are Agragesh Ramani and Avinash Ramani. They are from Chennai. Avinash is from a scientific and clinical background. He has a PhD in molecular biology. Agragesh has completed his MBA and looks after the business too. He is also the CEO of the company.
Trunome is an innovative diagnostic test. It is a non-invasive method that helps monitor the status of solid organ transplants through a blood test. It is also an effective way to monitor the health of transplanted solid organs such as the kidney, heart, liver, lungs, and pancreas. The organization offers specialized care solutions to support post-transplant recovery and long-term health. Trunome has some features like the Detection and monitoring of chronic diseases through blood tests and patented technology. They show results with 100% accuracy, CDSCO cleared facility, and US patent granted.
They have tested more than 5000 samples and impacted more than 1500 lives. They have confirmed a tie-up with India’s six hospitals with the vision to impact more than one billion people through Trunome, improve their quality and assure their physical, mental and emotional well-being.
Trunome Business Statistics:
Trunome’s one blood test costs around ₹41000, but the other competitors charge ₹2.47 lacs for the same blood test. Three world doctors at the shareholders in Trunome. Sales in 2021-2022 are 5 crores. The projected sales in 2022-2023 are 10 crores. EBITDA is 1 lakh per month. The monthly run rate of Trunome is 35 lakhs. The last round valuation was 75 crores.
What Problem Do They Solve?
Trunome Liquid Biopsy is a non-invasive diagnostic test. It enables the early detection and monitoring of chronic diseases through a blood test. This technology is protected by patents granted in the US because it is Asia’s first and entirely made-in-India technology platform. It is also known for its high effectiveness and accuracy in monitoring organ health. With innovation and technologies, they are tackling the most complex challenges in healthcare by revolutionizing early diagnosis of chronic and infectious diseases.
Please visit WEXT.in regularly for more details regarding Shark Tank India Season 2 updates. If you find this piece interesting, please forward it to your friends and leave feedback in the comment section.